Drug intelligence / Profile preview

CG006151

Development stage: Preclinical
Lead developer: Cullgen
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

CG006151 is a targeted protein degrader (TPD) being developed by Cullgen for the treatment of inflammatory diseases. Developed using Cullgen's proprietary uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) platform, CG006151 is designed to selectively recruit an E3 ubiquitin ligase to a specific pathogenic protein, leading to its ubiquitination and subsequent degradation by the proteasome. While the specific molecular target has not been disclosed, the program is part of Cullgen's pipeline focusing on expanding the application of protein degradation technology beyond oncology into immunology and inflammatory conditions.

Beyond the preview

Go deeper on CG006151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG006151.

Explore the full profile